Cytokine Release Syndrome

Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, according to findings published in Blood Advances.

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following haploidentical hematopoietic stem cell transplantation, according to results of a single-arm study.

The combination of talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.

SAN DIEGO — Epcoritamab exhibited encouraging efficacy among heavily pretreated patients with advanced chronic lymphocytic leukemia, according to study results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia, findings presented at ASH Annual Meeting and Exposition showed.

Chimeric antigen receptor T-cell therapy can be administered at community centers and on an outpatient basis with proper preparation, education and resources, according to prospective study results.

In this video, Douglas Tremblay, MD, discusses the results of a study into CD19-targeted chimeric antigen receptor T-cell therapy in acute lymphocytic leukemia presented at ESMO Congress 2024.

Chimeric antigen receptor T-cell therapy exhibited activity with minimal adverse effects for men with advanced prostate cancer, findings of a first-in-human trial showed.

Deleting the CD5 gene from chimeric antigen receptor T cells improved their expansion, durability and tumor-killing capabilities, according to study findings.

The FDA granted accelerated approval to afamitresgene autoleucel for certain adults with unresectable or metastatic synovial sarcoma.